463 related articles for article (PubMed ID: 33369720)
1. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
3. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
Bansal D; Reimers MA; Knoche EM; Pachynski RK
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477569
[TBL] [Abstract][Full Text] [Related]
5. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract][Full Text] [Related]
7. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
8. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
10. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
11. A New Era of Immunotherapy in Prostate Cancer.
Pizzola C; Rizvi SM; Joshi M
Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
13. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Zorko NA; Ryan CJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
[TBL] [Abstract][Full Text] [Related]
14. Immune-based therapies for metastatic prostate cancer: an update.
Hossain MK; Nahar K; Donkor O; Apostolopoulos V
Immunotherapy; 2018 Feb; 10(4):283-298. PubMed ID: 29421982
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
16. Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F
Cells; 2020 Sep; 9(9):. PubMed ID: 32911806
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
18. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
19. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
Jindal V
Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]